Dr. Neda Hashemi Sadraei, MD

Dr. Hashemi Sadraei practices at Ironwood Cancer & Research Centers in Mesa, Arizona.

Dr. Hashemi Sadraei's NPI, 1326393380, was assigned on July 16, 2012. Dr. Hashemi Sadraei holds New Mexico license MD2018-0028.

Dr. Hashemi Sadraei's primary practice is Ironwood Cancer & Research Centers, at 6111 E Arbor Ave, Mesa, AZ 85206 in Maricopa County. The practice phone is (480) 821-2838.

Dr. Hashemi Sadraei's primary practice is Ironwood Cancer & Research Centers in Mesa, Arizona. Dr. Hashemi Sadraei is also affiliated with University of New Mexico Hospital. The medical group on file is Ironwood Cancer & Research Centers. Dmand AI also links Dr. Hashemi Sadraei to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hashemi Sadraei practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hashemi Sadraei's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Hashemi Sadraei is licensed in New Mexico.

CMS data shows 401 Medicare services from Dr. Hashemi Sadraei across 5 procedure codes in 2024, for 140 Medicare patients. Medicare paid $27,774 for them. Every service was in an office.

CMS counts 140 Medicare patients who saw Dr. Hashemi Sadraei in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have cancer, and 66% have high blood pressure. 15% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hashemi Sadraei's median patient age at 72, with 35% women.

In 2024, Dr. Hashemi Sadraei wrote 192 Medicare Part D claims for 44 patients. 58% of them were for generic drugs. CMS names the drug for 99 of them, across 5 drugs with 11 or more claims each, at $313,604 in total drug cost. In 2023, CMS named 150 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Hashemi Sadraei for performance year 2024, reported as part of a group. Dr. Hashemi Sadraei accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hashemi Sadraei as offering telehealth.

CMS Open Payments shows 109 general payments to Dr. Hashemi Sadraei from 23 drug and device companies from 2016 to 2025. Compensation for serving as faculty or as a speaker for a medical education program make up the largest share, 56% of the total. Eisai Inc. paid the most, $76,877.